{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:11:09Z","timestamp":1761052269242,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Molecular Biology Unit, Department of Experimental Medicine and Biotechnology"},{"name":"PGIMER","award":["EMB2014\/3450"],"award-info":[{"award-number":["EMB2014\/3450"]}]},{"DOI":"10.13039\/501100001501","name":"UGC","doi-asserted-by":"publisher","award":["UNIGRANTS\/F.2-18.98"],"award-info":[{"award-number":["UNIGRANTS\/F.2-18.98"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.bcmd.2014.07.008","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T17:20:51Z","timestamp":1407864051000},"page":"132-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"54","author":[{"given":"Mansi","family":"Arora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelam","family":"Varma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.K.","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2014.07.008_bb0005","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ccr.2010.08.006","article-title":"The Notch\/Hes1 pathway sustains NF-\u03baB activation through CYLD repression in T cell leukemia","volume":"18","author":"Espinosa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcmd.2014.07.008_bb0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/path.2789","article-title":"Notch signalling in T-cell lymphoblastic leukaemia\/lymphoma and other haematological malignancies","volume":"223","author":"Aster","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.bcmd.2014.07.008_bb0015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nature01802","article-title":"The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination","volume":"424","author":"Kovalenko","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.07.008_bb0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ncponc0081","article-title":"Mechanisms of disease: inflammation and the origins of cancer","volume":"2","author":"Moss","year":"2005","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.bcmd.2014.07.008_bb0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/ni1315","article-title":"Regulation of T cell development by the deubiquitinating enzyme CYLD","volume":"7","author":"Reiley","year":"2006","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcmd.2014.07.008_bb0030","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1042\/BJ20120035","article-title":"Mechanism and specificity of the human paracaspase MALT1","volume":"443","author":"Hachmann","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcmd.2014.07.008_bb0035","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/emboj.2011.85","article-title":"T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1","volume":"30","author":"Staal","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.bcmd.2014.07.008_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/cdd.2009.43","article-title":"CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes","volume":"17","author":"Sun","year":"2010","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bcmd.2014.07.008_bb0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.gene.2013.03.058","article-title":"Regulation of cellular cyclin D1 gene by arsenic is mediated through miR-2909","volume":"522","author":"Sharma","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.bcmd.2014.07.008_bb0050","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2471\/BLT.08.050955","article-title":"The Declaration of Helsinki and public health","volume":"86","author":"Williams","year":"2008","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.bcmd.2014.07.008_bb0055","doi-asserted-by":"crossref","first-page":"37147","DOI":"10.1074\/jbc.M111.263384","article-title":"The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL\/lymphoma 10 (BCL10)-dependent NF-\u03baB activation","volume":"286","author":"Stempin","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2014.07.008_bb0060","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cell.2006.03.041","article-title":"Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling","volume":"125","author":"Massoumi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bcmd.2014.07.008_bb0065","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nature01811","article-title":"Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-\u03baB","volume":"424","author":"Brummelkamp","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.07.008_bb0070","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nature01802","article-title":"The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination","volume":"424","author":"Kovalenko","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.07.008_bb0075","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2006-07-025809","article-title":"Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications","volume":"109","author":"Jost","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2014.07.008_bb0080","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature04870","article-title":"Nuclear factor-kappaB in cancer development and progression","volume":"441","author":"Karin","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.07.008_bb0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.iy.12.040194.001041","article-title":"Function and activation of NF-kappaB in the immune system","volume":"12","author":"Baeuerle","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcmd.2014.07.008_bb0090","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2014.07.008_bb0095","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1742-4690-6-116","article-title":"T-cell activation promotes tumorigenesis in inflammation-associated cancer","volume":"6","author":"Rauch","year":"2009","journal-title":"Retrovirology"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979614000874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979614000874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:30:10Z","timestamp":1761049810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979614000874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S1079979614000874"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.07.008","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2014.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}